MedTrace Logo

TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial

NCT03636620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2018-08-17

No results posted yet for this study

Summary

This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.

Conditions

Interventions

DEVICE

Transcatheter arterial chemoembolization

Transcatheter arterial chemoembolization

DEVICE

radiofrequency ablation/microwave ablation

radiofrequency ablation/microwave ablation

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • zheng-gang Ren, doctor · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03636620 on ClinicalTrials.gov